Brian Robert Isett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brian Robert Isett has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Riyue Bao
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
30 shared publications - Lazar Vujanovic
University of Pittsburgh 2 Pittsburgh, PA
18 shared publications - Julie E. Bauman
George Washington University Medical Center, Washington, DC
17 shared publications - Robert L. Ferris
UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania
17 shared publications - Aditi Kulkarni
University of North Carolina at Chapel Hill 14 Chapel Hill, NC
16 shared publications - Arnab Chakravarti
Department of Radiation Oncology, The James Cancer Hospital/Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
16 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Elsevier in Pathology - Research and Practice
- Vol. 288
Spatial transcriptomic profiling of indeterminate antibody-mediated rejection in liver allografts: A pilot study
- 24 October 2026
- Published by Elsevier in Pathology - Research and Practice
- Vol. 288
Open AccessSpatial transcriptomic profiling of indeterminate antibody-mediated rejection in liver allografts: A pilot study
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Quantification of PD-L1+ cell densities by multispectral imaging
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Quantification of PD-L1+ cell densities by multispectral imaging
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Kaplan-Meier estimates of DFS by TP53 disruptive mutation status
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Kaplan-Meier estimates of DFS by TP53 disruptive mutation status
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Quantification of soluble serum analytes
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Quantification of soluble serum analytes
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Identification and visualization of circulating immune cell subsets by flow cytometry
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Identification and visualization of circulating immune cell subsets by flow cytometry
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Quantification of circulating immune cell subsets
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Quantification of circulating immune cell subsets
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Representativeness of Study Participants
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Representativeness of Study Participants
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Antibodies and dilutions used for multispectral imaging
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Antibodies and dilutions used for multispectral imaging
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Antibodies and dilutions used for spectral flow cytometry
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Antibodies and dilutions used for spectral flow cytometry
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Multispectral imaging – descriptive statistics (n=34)
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma
Multispectral imaging – descriptive statistics (n=34)